🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/11/2007 | 25,63 | 25,63 | 24,84 | 25,08 | -2,45% | 3,08% | 2.475.400 |
| 16/11/2007 | 26,33 | 26,51 | 25,68 | 25,71 | -1,57% | 3,15% | 1.536.400 |
| 15/11/2007 | 26,00 | 27,15 | 25,72 | 26,12 | +0,62% | 5,50% | 2.142.500 |
| 14/11/2007 | 26,08 | 26,66 | 25,61 | 25,96 | -1,03% | 4,03% | 1.746.200 |
| 13/11/2007 | 26,06 | 26,34 | 25,40 | 26,23 | +0,65% | 3,61% | 2.269.400 |
| 12/11/2007 | 25,40 | 26,99 | 25,10 | 26,06 | +2,52% | 7,44% | 2.669.200 |
| 09/11/2007 | 25,15 | 26,31 | 24,83 | 25,42 | -0,55% | 5,88% | 2.379.300 |
| 08/11/2007 | 25,88 | 26,12 | 24,77 | 25,56 | +3,19% | 5,22% | 3.601.800 |
| 07/11/2007 | 24,81 | 25,28 | 24,38 | 24,77 | -1,12% | 3,63% | 3.103.300 |
| 06/11/2007 | 24,01 | 26,25 | 24,01 | 25,05 | +4,03% | 9,33% | 6.810.500 |
| 05/11/2007 | 25,97 | 26,00 | 22,92 | 24,08 | -16,68% | 11,86% | 11.767.100 |
| 02/11/2007 | 28,80 | 29,87 | 26,65 | 28,90 | -8,66% | 11,18% | 9.227.800 |
| 01/11/2007 | 32,30 | 32,34 | 31,50 | 31,64 | -2,16% | 2,60% | 1.711.400 |
| 31/10/2007 | 31,94 | 32,39 | 31,29 | 32,34 | +1,25% | 3,44% | 1.909.800 |
| 30/10/2007 | 31,66 | 32,49 | 31,62 | 31,94 | -3,04% | 2,75% | 2.492.800 |
| 29/10/2007 | 32,09 | 32,94 | 32,00 | 32,94 | +1,95% | 2,93% | 1.452.000 |
| 26/10/2007 | 32,56 | 32,79 | 31,85 | 32,31 | +0,03% | 2,89% | 1.459.300 |
| 25/10/2007 | 32,30 | 32,60 | 31,65 | 32,30 | +1,35% | 2,94% | 1.720.300 |
| 24/10/2007 | 31,94 | 32,29 | 31,03 | 31,87 | -1,21% | 3,94% | 1.779.600 |
| 23/10/2007 | 31,52 | 32,26 | 31,15 | 32,26 | +1,38% | 3,52% | 2.022.500 |
| 22/10/2007 | 30,56 | 32,20 | 30,17 | 31,82 | +3,55% | 6,64% | 2.929.900 |
| 19/10/2007 | 30,78 | 31,53 | 29,50 | 30,73 | -1,19% | 6,60% | 3.391.100 |
| 18/10/2007 | 32,70 | 33,00 | 28,78 | 31,10 | -13,18% | 12,91% | 16.416.300 |
| 17/10/2007 | 36,16 | 36,44 | 34,86 | 35,82 | +0,03% | 4,37% | 991.300 |
| 16/10/2007 | 36,00 | 36,41 | 35,61 | 35,81 | -0,75% | 2,22% | 1.138.400 |
| 15/10/2007 | 35,55 | 36,51 | 35,55 | 36,08 | +0,87% | 2,70% | 1.190.200 |
| 12/10/2007 | 36,24 | 36,97 | 35,36 | 35,77 | -1,41% | 4,44% | 1.363.700 |
| 11/10/2007 | 36,35 | 37,23 | 36,12 | 36,28 | -0,19% | 3,05% | 1.237.600 |
| 10/10/2007 | 35,48 | 36,60 | 35,40 | 36,35 | +2,02% | 3,38% | 1.684.700 |
| 09/10/2007 | 36,49 | 36,51 | 35,14 | 35,63 | -2,62% | 3,75% | 1.698.100 |